scholarly journals Adult-onset citrullinemia type I

2020 ◽  
Author(s):  
2016 ◽  
Vol 33 (2) ◽  
pp. 98-100
Author(s):  
Fauzia Mohsin ◽  
Sharmin Mahbuba ◽  
Tahmina Begum ◽  
Narayan Chandra Saha ◽  
Kishwar Azad ◽  
...  

Citrullinemia type I (CTLN1) is an inherited urea cycle disorder where the enzyme argininosuccinate synthetase is deficient. It can lead to recurrent hyperammonemic crisis that may result in permanent neurological sequelae, even death. Vomiting in patients with urea cycle disorders may either be the result or cause of acute hyperammonemia, particularly if due to an illness that leads to catabolism. Therefore, age-appropriate common etiologies of vomiting must be considered when evaluating these patients. We present a case of a 2 year 5 month old female child with CTLN1 who had a history of frequent vomiting after the age of one year and some recent neurological manifestations like excessive crying and lethargy and one episode of unconsciousness. Investigations revealed high level of ammonia. Amino acid profile using tandem mass spectrometry showed markedly increased plasma level of citrulline. After administration of sodium benzoate and protein restricted diet there was dramatic improvement of all the symptoms.J Bangladesh Coll Phys Surg 2015; 33(2): 98-100


QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Radwa Gamal ◽  
Ola A Khalifa

Abstract Citrullinemia type I (CTLN1) clinical spectrum includes an acute neonatal form ("classic" form) and a milder late-onset form (“non-classic" form). Infants with classic form appear normal at birth. Shortly thereafter, they experienced hyperammonemia and develops symptoms. Without prompt intervention, rapid neurological deterioration with seizures, spasticity, loss of consciousness and even death can occur. Continuous venovenous hemofiltration should be started in neonates and children with ammonia levels > 500 µmol/L or even at lower levels if there has been an inadequate response to medical management after 4 hours. Alternatively, but only in centers that lack ability or expertise to perform extracorporeal therapy, peritoneal dialysis can be utilized. The hallmarks of dialysis is rapid lowering of plasma ammonia concentration to avoid neurotoxicity and irreversible brain damage. Objectives To evaluate the effect of peritoneal dialysis on plasma ammonia levels and the clinical outcome in an encephalopathic Egyptian patient with CTLN1. Patient and Methods A 2.5 year old male patient with a classical form of CTLN1was recruited. The first presenting symptom of the patient was poor suckling and disturbed conscious level at the age of 5 day. He was admitted to neonatal intensive-care unit (NICU) with hyperammonemic encephalopathy and abnormal pattern of breathing. He developed apneic attack and underwent mechanical ventilation. The diagnosis of CTLN1 was established with elevated plasma ammonia concentration (350 µmol/L) and plasma citrulline concentration (2570 µmol/L). The patient was managed with peritoneal dialysis for 4 days, together with protein restriction, sodium benzoate, arginine therapy and high caloric intake. Results Plasma ammonia level was decreased with improvement of general condition and conscious level after dialysis. Upon discharge from NICU, the patient was referred to our Genetic clinic and no history of further hospital admission since then. Mild developmental delay mainly cognitive was noted during his regular clinic follow up. Conclusion CTLN1 can present with hyperammonemic encephalopathy which could be lethal if not promptly managed. Peritoneal dialysis proved to be an effective therapy of reducing plasma ammonia rapidly and improving outcome of the patient.


Neurogenetics ◽  
2020 ◽  
Vol 21 (3) ◽  
pp. 179-186
Author(s):  
Pınar Gelener ◽  
Mariasavina Severino ◽  
Sevda Diker ◽  
Kerem Teralı ◽  
Gulten Tuncel ◽  
...  

2009 ◽  
Vol 42 (10-11) ◽  
pp. 1166-1168 ◽  
Author(s):  
Laura E. Laróvere ◽  
Celia J. Angaroni ◽  
Sandra L. Antonozzi ◽  
Miriam B. Bezard ◽  
Mariko Shimohama ◽  
...  

Neurology ◽  
2002 ◽  
Vol 59 (11) ◽  
pp. 1802-1804 ◽  
Author(s):  
O. Bahr ◽  
I. Mader ◽  
J. Zschocke ◽  
J. Dichgans ◽  
J.B. Schulz

Neurogenetics ◽  
2015 ◽  
Vol 16 (4) ◽  
pp. 325-328 ◽  
Author(s):  
T. M. Pierson ◽  
Mani Nezhad ◽  
Matthew A. Tremblay ◽  
Richard Lewis ◽  
Derek Wong ◽  
...  

Neurology ◽  
2006 ◽  
Vol 67 (10) ◽  
pp. 1895-1896 ◽  
Author(s):  
M. Eriguchi ◽  
H. Mizuta ◽  
K. Kurohara ◽  
M. Kosugi ◽  
Y. Yakushiji ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document